

Table 1. Antibody therapeutics first approved in Europe or the US during January-June 2016

International non-proprietary name	Brand name	Target; Format	Indication under review	Location of approval
Atezolizumab	Tencentriq	PD-L1; Humanized IgG1	Bladder cancer	US
Reslizumab	Cinqair	IL-5; Humanized IgG4	Asthma	US
Obiltoximab	Anthim	Protective antigen of <i>B. anthracis</i> exotoxin; Chimeric IgG1	Prevention of inhalational anthrax	US
Ixekizumab	Taltz	IL-17a; Humanized IgG4	Psoriasis	EU, US

Table 2. Antibody therapeutics undergoing a first regulatory review in Europe or the US*

International non-proprietary name	Brand name	Target; Format	Indication under review	Location of review
Romosozumab	(Pending)	Sclerostin; Humanized IgG2	Osteoporosis in postmenopausal women at increased risk of fracture	US
Inotuzumab ozogamicin	(Pending)	CD22; Humanized IgG4; ADC	Hematological malignancy	EU
Ocrelizumab	OCREVUS	CD20; Humanized IgG1	Multiple sclerosis	EU, US
(Pending)	Xilonix	IL-1 alpha; Human IgG1	Advanced colorectal cancer	EU
Bezlotoxumab	Zinplava	<i>Clostridium difficile</i> enterotoxin B; Human IgG1	Prevention of <i>Clostridium difficile</i> infection recurrence	EU, US
Brodalumab	(Pending)	IL-17R; Human IgG2	Immune-mediated disorders	EU, US
Sarilumab	(Pending)	IL-6R; Human IgG1	Rheumatoid arthritis	US
Olaratumab	(Pending)	PDGFR α ; Human IgG1	Soft tissue sarcoma	EU, US

*Data available as of July 25, 2016.